Bioqual Inc (BIOQ)
OTHER OTC:BIOQ
Want to see BIOQ full AI Analyst Report?
Top Page
Bioqual
(OTC:BIOQ)
Select Model
Select Model
Rating:46Neutral
Price Target:
$35.00
▼(-9.68% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by deteriorating operating performance (losses, negative gross profit, and multi-year revenue declines). Technicals also remain bearish with the price below all key moving averages and negative MACD, despite oversold readings. Balance sheet and cash flow are comparatively better (positive operating/free cash flow and still-serviceable capitalization), but rising leverage and weaker coverage temper the support.
Positive Factors
Balance Sheet Health
Solid equity and a still-serviceable capital structure give the company durable financial flexibility to fund operations, absorb losses, and pursue recovery initiatives over the next several months. This reduces short-term refinancing pressure and supports strategic options while profitability is restored.
Negative Factors
Multi-year Revenue Decline
Three straight years of revenue decline and a ~26% drop most recently reflect weakening demand or pricing power, a structural risk to long-term recovery. Persistent top-line erosion undermines margins, cash generation and the ability to leverage fixed costs toward sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Health
Solid equity and a still-serviceable capital structure give the company durable financial flexibility to fund operations, absorb losses, and pursue recovery initiatives over the next several months. This reduces short-term refinancing pressure and supports strategic options while profitability is restored.
Read all positive factors
Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.25M
Dividend YieldN/A
Average Volume (3M)223.00
Price to Earnings (P/E)―
Beta (1Y)-0.12
Revenue Growth-13.57%
EPS Growth41.93%
CountryUS
Employees278
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.84
Shares Outstanding893,838
10 Day Avg. Volume0
30 Day Avg. Volume223
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.11
Price to Sales (P/S)0.82
P/FCF Ratio14.87
Enterprise Value/Market Cap1.73
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit-14.54
Enterprise Value/Ebitda345.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioqual Business Overview & Revenue Model
Company Description
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus i...
Bioqual Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Aug 2024 | Aug 2023 | May 2023 | Aug 2021 | Aug 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.49M | 48.87M | 58.59M | 62.66M | 66.15M | 57.68M |
| Gross Profit | -3.84M | -1.90M | 7.43M | 12.60M | 13.01M | 13.97M |
| EBITDA | 161.27K | 509.61K | 3.03M | 6.97M | 14.76M | 13.07M |
| Net Income | -986.47K | -1.05M | 483.48K | 835.55K | 5.26M | 6.33M |
Balance Sheet | ||||||
| Total Assets | 71.77M | 57.12M | 56.59M | 61.32M | 63.34M | 53.42M |
| Cash, Cash Equivalents and Short-Term Investments | 13.29M | 17.85M | 15.59M | 7.28M | 2.18M | 7.72M |
| Total Debt | 33.48M | 16.54M | 3.59M | 18.61M | 18.72M | 14.62M |
| Total Liabilities | 36.75M | 20.96M | 18.94M | 23.70M | 25.67M | 19.89M |
| Stockholders Equity | 35.02M | 36.15M | 37.65M | 37.61M | 37.67M | 33.53M |
Cash Flow | ||||||
| Free Cash Flow | 4.89M | 2.71M | 8.76M | 5.99M | -4.57M | -2.26M |
| Operating Cash Flow | 5.24M | 2.94M | 9.36M | 8.23M | 313.36K | 2.15M |
| Investing Cash Flow | -6.75M | -238.78K | -597.13K | -2.24M | -4.73M | -3.70M |
| Financing Cash Flow | 0.00 | -447.21K | -447.21K | -894.42K | -1.12M | -983.86K |
Bioqual Technical Analysis
Negative
38.75
Price Trends
36.64
Negative
37.61
Negative
39.69
Negative
Market Momentum
-0.14
Negative
20.97
Positive
50.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 38.75 is above the 20-day moving average (MA) of 36.08, above the 50-day MA of 36.64, and below the 200-day MA of 39.69, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 20.97 is Positive, neither overbought nor oversold. The STOCH value of 50.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.
Bioqual Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $53.15M | -101.61 | -2.78% | ― | 29.77% | 90.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.87M | -0.32 | -56.22% | ― | -7.37% | 94.04% | |
47 Neutral | $20.92M | -23.37 | 76.82% | ― | 40.04% | 30.25% | |
46 Neutral | $32.25M | -11.14 | -2.84% | ― | -13.57% | 41.93% | |
46 Neutral | $99.46M | -1.46 | -1760.83% | ― | 24.08% | 32.65% | |
42 Neutral | $10.63M | -0.17 | -44.77% | ― | 8.19% | 56.09% |
* Healthcare Sector Average
BIOQ
Bioqual
36.08
-21.42
-37.26%
NOTV
Inotiv
0.31
-1.67
-84.39%
VNRX
VolitionRX
2.64
-7.11
-72.92%
PRPO
Precipio
29.80
23.45
369.29%
BNGO
BioNano Genomics
1.16
-2.84
-71.00%
BDSX
Biodesix
9.84
-0.68
-6.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.